FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207625114> ?p ?o ?g. }

• W3207625114 abstract "Objective: To describe the baseline characteristics for subjects in the ongoing CLARITY AD study. Background: BAN2401 is a humanized IgG1 monoclonal antibody that selectively targets soluble aggregated Aβ species. Based on encouraging results from a phase 2 study, the CLARITY AD phase 3 study was designed to confirm the efficacy and safety of BAN2401 in patients with early Alzheimer’s disease. Design/Methods: CLARITY AD is an 18-month treatment, multicenter, double-blind, placebo-controlled, parallel-group study with open-label extension in patients with early AD. Baseline clinical and demographic data was summarized descriptively and compared to the BAN2401 phase 2 study population. Results: As of a data cutoff of June 22, 2020, a total of 801 subjects were enrolled in CLARITY AD. The median age of subjects was 73 years (range: 50–89 years), with 83% of patients 65 years of age or older. Overall, 51% of subjects were female and 78% were Caucasian. Mean (SD) baseline values for clinical endpoints were 3.3 (1.3) for CDR-SB, 0.4 (0.1) for ADCOMS, 25.2 (7.2) for ADAS-Cog, 25.6 (2.2) for MMSE, and 0.6 (0.2) for Global CDR. Aggregate baseline characteristics are similar to the BAN2401 phase 2 study (median age 72 years [range: 50–90 years]; 80% 65 years of age or older; 50% female; 90% Caucasian; clinical endpoints: 3.0 [1.4] for CDR-SB, 0.4 [0.2] for ADCOMS, 22.2 [7.4] for ADAS-Cog, 25.6 [2.4] for MMSE, and 0.6 [0.2] for Global CDR). Comparisons of the study populations will be presented. Conclusions: Building on the encouraging findings from the BAN2401 phase 2 study, the phase 3 CLARITY AD study is designed to confirm clinical efficacy and safety of BAN2401 versus placebo in patients with early AD. Baseline characteristics after enrollment of 801 subjects are consistent with previous studies and representative of an early AD population. Enrollment is ongoing. Disclosure: Shau Yu Lynch has received personal compensation for serving as an employee of Eisai. Dr. Irizarry has received personal compensation for serving as an employee of Eisai, Inc.. Shobha Dhadda has received personal compensation for serving as an employee of Eisai Inc. Dr. Bogoslovsky has received personal compensation for serving as an employee of Eisai Inc. Larisa Reyderman has nothing to disclose. June Kaplow has received personal compensation for serving as an employee of Eisai Inc.. June Kaplow has a non-compensated relationship as a Participant member with ADNI that is relevant to AAN interests or activities. Martin Rabe, M.Sc. has received personal compensation for serving as an employee of Eisai Inc. Dr. Kramer has received personal compensation for serving as an employee of Eisai Inc. Harald Hampel has received personal compensation for serving as an employee of Eisai Inc.. Chad J Swanson has nothing to disclose." @default.
• W3207625114 created "2021-10-25" @default.
• W3207625114 creator A5015176052 @default.
• W3207625114 creator A5028236243 @default.
• W3207625114 creator A5031104672 @default.
• W3207625114 creator A5044763521 @default.
• W3207625114 creator A5048619898 @default.
• W3207625114 creator A5064852158 @default.
• W3207625114 creator A5066715069 @default.
• W3207625114 creator A5075884817 @default.
• W3207625114 creator A5081950273 @default.
• W3207625114 creator A5090798839 @default.
• W3207625114 date "2021-04-13" @default.
• W3207625114 modified "2023-09-24" @default.
• W3207625114 title "BASELINE CHARACTERISTICS FOR CLARITY-AD: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 18-MONTH STUDY EVALUATING BAN2401 IN EARLY ALZHEIMER’S DISEASE (3021)" @default.
• W3207625114 hasPublicationYear "2021" @default.
• W3207625114 type Work @default.
• W3207625114 sameAs 3207625114 @default.
• W3207625114 citedByCount "0" @default.
• W3207625114 crossrefType "journal-article" @default.
• W3207625114 hasAuthorship W3207625114A5015176052 @default.
• W3207625114 hasAuthorship W3207625114A5028236243 @default.
• W3207625114 hasAuthorship W3207625114A5031104672 @default.
• W3207625114 hasAuthorship W3207625114A5044763521 @default.
• W3207625114 hasAuthorship W3207625114A5048619898 @default.
• W3207625114 hasAuthorship W3207625114A5064852158 @default.
• W3207625114 hasAuthorship W3207625114A5066715069 @default.
• W3207625114 hasAuthorship W3207625114A5075884817 @default.
• W3207625114 hasAuthorship W3207625114A5081950273 @default.
• W3207625114 hasAuthorship W3207625114A5090798839 @default.
• W3207625114 hasConcept C126322002 @default.
• W3207625114 hasConcept C142724271 @default.
• W3207625114 hasConcept C203092338 @default.
• W3207625114 hasConcept C204787440 @default.
• W3207625114 hasConcept C27081682 @default.
• W3207625114 hasConcept C2908647359 @default.
• W3207625114 hasConcept C31760486 @default.
• W3207625114 hasConcept C535046627 @default.
• W3207625114 hasConcept C71924100 @default.
• W3207625114 hasConcept C99454951 @default.
• W3207625114 hasConceptScore W3207625114C126322002 @default.
• W3207625114 hasConceptScore W3207625114C142724271 @default.
• W3207625114 hasConceptScore W3207625114C203092338 @default.
• W3207625114 hasConceptScore W3207625114C204787440 @default.
• W3207625114 hasConceptScore W3207625114C27081682 @default.
• W3207625114 hasConceptScore W3207625114C2908647359 @default.
• W3207625114 hasConceptScore W3207625114C31760486 @default.
• W3207625114 hasConceptScore W3207625114C535046627 @default.
• W3207625114 hasConceptScore W3207625114C71924100 @default.
• W3207625114 hasConceptScore W3207625114C99454951 @default.
• W3207625114 hasLocation W32076251141 @default.
• W3207625114 hasOpenAccess W3207625114 @default.
• W3207625114 hasPrimaryLocation W32076251141 @default.
• W3207625114 hasRelatedWork W2800288795 @default.
• W3207625114 hasRelatedWork W2802264099 @default.
• W3207625114 hasRelatedWork W2803651213 @default.
• W3207625114 hasRelatedWork W2804412694 @default.
• W3207625114 hasRelatedWork W2806923811 @default.
• W3207625114 hasRelatedWork W2808054523 @default.
• W3207625114 hasRelatedWork W2808217727 @default.
• W3207625114 hasRelatedWork W2866875357 @default.
• W3207625114 hasRelatedWork W2884571446 @default.
• W3207625114 hasRelatedWork W2885049414 @default.
• W3207625114 hasRelatedWork W2888223345 @default.
• W3207625114 hasRelatedWork W2894489394 @default.
• W3207625114 hasRelatedWork W2919817085 @default.
• W3207625114 hasRelatedWork W2973602172 @default.
• W3207625114 hasRelatedWork W3019112891 @default.
• W3207625114 hasRelatedWork W3156802418 @default.
• W3207625114 hasRelatedWork W3183081226 @default.
• W3207625114 hasRelatedWork W3198538026 @default.
• W3207625114 hasRelatedWork W3199451569 @default.
• W3207625114 hasRelatedWork W744842035 @default.
• W3207625114 hasVolume "96" @default.
• W3207625114 isParatext "false" @default.
• W3207625114 isRetracted "false" @default.
• W3207625114 magId "3207625114" @default.
• W3207625114 workType "article" @default.